Company news
Quantum Biopharma Ltd. Subordinate Voting Shares Class B (CSE:QNTM) news
Quantum Biopharma Ltd. Subordinate Voting Shares Class B news releases on 6ix. Latest, May 19, 2025: Quantum Biopharma Purchases an Additional USD $1 Million…
View Quantum Biopharma Ltd. Subordinate Voting Shares Class B →
Press releases — page 3
Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000
May 19, 2025
Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
May 16, 2025
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
May 12, 2025
Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
May 5, 2025
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time
April 24, 2025
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor
April 22, 2025
Quantum BioPharma Corporate Update
April 17, 2025
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario
April 14, 2025
Quantum BioPharma Licensee Celly Nutrition Announces Landmark Partnership with the Asian American Trade Associations Council (AATAC) to Expand Retail Availability of its Alcohol Detox Beverage unbuzzd(TM)
April 10, 2025
Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico
April 3, 2025
Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis
April 1, 2025
Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms
March 31, 2025
Quantum BioPharma Provides Corporate Update
March 30, 2025
Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
March 28, 2025
Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors
March 27, 2025
Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd(TM) Alcohol Detox Product Lineup for Retail Sales
March 26, 2025
Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
March 20, 2025
Quantum BioPharma Unaware of Any Material Change
March 17, 2025
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
February 26, 2025
Quantum BioPharma Continues to Diversify its Treasury with the Purchase of Another USD $1,000,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
February 18, 2025
Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
February 11, 2025
Quantum Biopharma in Court With Dr. Raza Bokhari on January 24, 2025 Seeking a Court Order to Declare Him to Be a Vexatious Litigant and Other Litigation Updates
January 17, 2025
Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM
January 14, 2025
Quantum Biopharma Ltd. Approved to Dual List on Upstream
January 7, 2025
Quantum Biopharma Announces Closing of Second Tranche
December 20, 2024
Quantum Biopharma Diversifies Treasury With the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency
December 20, 2024
Quantum Biopharma Announces Closing of First Tranche
December 13, 2024
Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)
December 10, 2024
Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million
December 5, 2024
Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation
November 25, 2024
Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia
October 29, 2024
Quantum Biopharma (NASDAQ:QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
October 22, 2024
Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
October 21, 2024
Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
October 21, 2024
Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America
October 7, 2024
Quantum BioPharma Ltd. Pharma Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group Across Puerto Rico, the Caribbean, and Parts of Central and South America
October 7, 2024
Quantum Biopharma Provides Corporate Update
September 27, 2024
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Invesments and Kingswood US
September 25, 2024
Quantum BioPharma Closes Private Placement Offering
September 12, 2024
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
September 9, 2024
Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements
September 6, 2024
Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon.com so you can "own NOW and what's NEXT"
August 30, 2024
FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation - Trading Under New Ticker Symbol "QNTM"
August 15, 2024
FSD Pharma Announces Share Consolidation and Name Change
August 8, 2024
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team
August 9, 2024
24/7 Market News Publishes Report Covering Functional Beverage Market, Featuring FSD Pharma
July 25, 2024
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
July 23, 2024
24/7 Market News Publishes Report Covering Biotech Developments, Featuring FSD Pharma
July 23, 2024
FSD Pharma Files Amended and Restated Material Change Report
July 4, 2024
FSD Pharma provides Corporate Update
June 28, 2024